Skip to main content

CORRECTION article

Front. Med., 26 October 2021
Sec. Gastroenterology
Volume 8 - 2021 | https://doi.org/10.3389/fmed.2021.785148

Corrigendum: Development and Characterization of a New Endoscopic Drug-Eluting Platform With Proven Efficacy in Acute and Chronic Experimental Colitis

This article is a correction to:

  1. Development and Characterization of a New Endoscopic Drug-Eluting Platform With Proven Efficacy in Acute and Chronic Experimental Colitis

    1. Read original article
\nIgnacio BonIgnacio Bon1Mary Cano-SarabiaMary Cano-Sarabia2Napoleon de la OssaNapoleon de la Ossa3Ramon Bartolí, &#x;Ramon Bartolí1,4*†Vicente Lorenzo-Zúiga, &#x;Vicente Lorenzo-Zúñiga1,5*†
  • 1Health Research Institute Germans Trias i Pujol (IGTP), Barcelona, Spain
  • 2Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus de la UAB, Bellaterra, Spain
  • 3Servicio de Anatomia Patológica, Hospital Universitari General de Catalunya—Grupo Quirón Salud, Barcelona, Spain
  • 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
  • 5Endoscopy Unit, University Hospital La Fe, Valencia, Spain

A Corrigendum on
Development and Characterization of a New Endoscopic Drug-Eluting Platform With Proven Efficacy in Acute and Chronic Experimental Colitis

by Bon, I., Cano-Sarabia, M., de la Ossa, N., Bartolí, R., and Lorenzo-Zúñiga, V. (2020). Front. Med. 7:415. doi: 10.3389/fmed.2020.00415

There is an error in the Funding statement. Instead of “Health Institute carlos III”, the correct name for the funder is “Instituto de Salud Carlos III (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: drug-eluting, experimental colitis, endoscopic shielding technique, hydrogel, endoscopy

Citation: Bon I, Cano-Sarabia M, de la Ossa N, Bartolí R and Lorenzo-Zúñiga V (2021) Corrigendum: Development and Characterization of a New Endoscopic Drug-Eluting Platform With Proven Efficacy in Acute and Chronic Experimental Colitis. Front. Med. 8:785148. doi: 10.3389/fmed.2021.785148

Received: 28 September 2021; Accepted: 05 October 2021;
Published: 26 October 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Bon, Cano-Sarabia, de la Ossa, Bartolí and Lorenzo-Zúñiga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ramon Bartolí, rbartolisole@gmail.com; Vicente Lorenzo-Zúñiga, vlorenzozuniga@gmail.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.